You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: April 1, 2025

Patent: 5,496,801


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 5,496,801
Title: Parathyroid hormone formulation
Abstract:Described herein are preparations containing parathyroid hormone that has been stablized with an excipient and buffering agent. Preferred preparations incorporate human PTH(1-84), mannitol as excipient and citrate as buffering agent, and are incorporated in vials as a freeze-dried powder for reconstitution to treat osteoporosis.
Inventor(s): Holthuis; Josephus J. M. (AJ Leiden, NL), Mekking; Albert (CR Woerden, NL), Voetman; Alwinus A. (DT Zwanenburg, NL)
Assignee: Allelix BioPharmaceuticals Inc. (Ontario, CA)
Application Number:08/172,206
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

Analyzing the Claims and Patent Landscape of United States Patent 5,496,801

Introduction

United States Patent 5,496,801, titled "Parathyroid Hormone Formulation," is a significant patent in the pharmaceutical industry, particularly in the field of hormone therapies. This analysis will delve into the claims of the patent, the patent landscape, and the implications of recent regulatory and technological developments.

Background of the Patent

The patent, issued to a pharmaceutical company, covers formulations of parathyroid hormone (PTH) used in the treatment of various bone-related disorders. The patent was originally set to expire on December 23, 2013, but due to regulatory review periods, it was extended until December 23, 2018[1].

Claims of the Patent

The patent claims cover specific formulations of PTH, including the methods of preparation and the compositions themselves. These claims are critical as they define the scope of protection for the invention.

Formulation Claims

  • The patent includes claims for the formulation of PTH in various delivery systems, such as injectable solutions and lyophilized powders.
  • These formulations are designed to enhance the stability and efficacy of PTH, which is crucial for its therapeutic use[1].

Method Claims

  • The patent also claims methods for preparing these formulations, including steps for purification, stabilization, and packaging.
  • These method claims are important as they protect the proprietary processes developed by the patent holder[1].

Patent Landscape

The patent landscape surrounding U.S. Patent 5,496,801 is complex and dynamic, especially in the biotechnology and pharmaceutical sectors.

Prior Art and Patentability

  • Conducting a thorough prior art search is essential to ensure the novelty and non-obviousness of the invention. This involves searching through patents, scientific literature, and other non-patent literature to identify any existing similar formulations or methods[3].
  • Tools like CAS SciFinder and CAS STNext can be invaluable in navigating this complex landscape by providing access to comprehensive databases of patents and scientific literature[3].

Freedom-to-Operate (FTO) Searches

  • FTO searches are crucial to determine whether the commercialization of the patented formulation would infringe on existing patents.
  • These searches must be tailored to the specific geographic regions where the product will be marketed, considering the claims of in-force patents in those regions[3].

IP Entanglements

  • IP entanglements, such as cross-licensing agreements, research collaborations, and mergers and acquisitions, can significantly impact the patentability and commercialization of the invention.
  • Identifying and managing these entanglements is essential to ensure that the company has the freedom to operate and innovate without legal hurdles[3].

Regulatory Considerations

The extension of the patent term until December 23, 2018, was based on regulatory review periods, highlighting the importance of regulatory compliance.

Patent Term Extension

  • The patent term was extended under 35 U.S.C. § 156, which allows for the extension of a patent term due to delays in the regulatory approval process[1].
  • This extension is critical as it provides additional time for the patent holder to recoup investments and maintain market exclusivity.

Use of AI in Patent Applications

  • Recent guidance from the USPTO emphasizes the need for careful review of documents generated or assisted by AI tools to ensure accuracy and compliance with the duty of candor and good faith[2].
  • This is particularly relevant in complex scientific industries where AI may be used to draft portions of the patent application, including claims and specifications.

Impact of Technological Advancements

Technological advancements, especially in AI and data analytics, are transforming the way patent searches and analyses are conducted.

AI Tools in Patent Searches

  • AI tools can assist in identifying prior art and analyzing patent landscapes more efficiently, but they must be used with caution to avoid errors and omissions[2].
  • Practitioners must verify the technical accuracy of documents drafted using AI tools to ensure they meet the standards required by the USPTO[2].

Data Analytics and Patent Optimization

  • Tools like LexisNexis PatentOptimizer can help in conducting objective and comprehensive reviews of patent applications, reducing the risk of procedural objections and post-grant challenges[5].
  • These tools can analyze the substance and form of the patent application, helping to produce stronger and more defensible patents.

Global Patent System Integration

The global patent system is becoming more integrated, which affects how patent searches and analyses are conducted.

Global Dossier and Common Citation Document

  • Services like the Global Dossier and the Common Citation Document (CCD) provide a single point of access to citation data and file histories of related applications from participating IP offices, facilitating a more streamlined and comprehensive search process[4].

Public Search Facilities and PTRCs

  • Resources such as the USPTO Public Search Facility and Patent and Trademark Resource Centers (PTRCs) offer public access to patent and trademark information, aiding in thorough patentability assessments[4].

Key Takeaways

  • Comprehensive Prior Art Search: Conduct thorough searches using advanced tools to ensure novelty and non-obviousness.
  • Regulatory Compliance: Understand and comply with regulatory requirements, including the use of AI tools.
  • Freedom-to-Operate: Perform FTO searches tailored to the commercialization strategy.
  • IP Entanglements: Identify and manage IP entanglements to ensure freedom to operate.
  • Technological Integration: Leverage AI and data analytics tools while ensuring accuracy and compliance.

FAQs

Q: What is the significance of the patent term extension for U.S. Patent 5,496,801?

A: The patent term extension until December 23, 2018, allows the patent holder additional time to recoup investments and maintain market exclusivity due to delays in the regulatory approval process.

Q: How do AI tools impact the drafting of patent applications?

A: AI tools can assist in drafting patent applications but must be reviewed carefully to ensure accuracy and compliance with the duty of candor and good faith. Any material contributions by AI must be disclosed to the USPTO.

Q: What are the challenges in conducting a prior art search for complex scientific innovations?

A: The challenges include navigating complex technologies, identifying relevant prior art from diverse sources, and dealing with inconsistent terminology and incomplete indexing.

Q: How can tools like CAS SciFinder and LexisNexis PatentOptimizer aid in patent analysis?

A: These tools provide access to comprehensive databases, help in identifying prior art, and conduct objective reviews of patent applications to produce stronger and more defensible patents.

Q: What is the importance of Global Dossier and Common Citation Document in patent searches?

A: These services integrate citation data and file histories from multiple IP offices, facilitating a more streamlined and comprehensive search process.

Sources

  1. Regulations.gov: "Attachment 1: U.S. Patent No. 5,496,801 PARATHYROID HORMONE FORMULATION"
  2. BIPC: "U.S. Patent Office Issues Additional Guidance on Use of AI Tools"
  3. CAS.org: "Navigating patentability assessments in scientific industries"
  4. USPTO: "Search for patents"
  5. LexisNexis IP: "Patent Analysis Tools for Objective Application Review"

More… ↓

⤷  Try for Free

Details for Patent 5,496,801

ApplicantTradenameBiologic IngredientDosage FormBLAApproval DatePatent No.Expiredate
Merck Sharp & Dohme Llc ZOSTAVAX zoster vaccine live For Injection 125123 May 25, 2006 5,496,801 2039-03-29
Takeda Pharmaceuticals U.s.a., Inc. NATPARA parathyroid hormone For Injection 125511 January 23, 2015 5,496,801 2039-03-29
>Applicant>Tradename>Biologic Ingredient>Dosage Form>BLA>Approval Date>Patent No.>Expiredate
Showing 1 to 2 of 2 entries

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.